During organ turnover, robust mechanisms enforce a balanced equilibrium between cell division and death [1, 2] . Nascent tumors must destabilize these mechanisms to subvert cell equilibrium for cancerous growth [3] [4] [5] [6] [7] . The nature of these destabilizing events is central to understanding how new tumors become established and may suggest strategies for cancer prevention. One of the best characterized mechanisms for cell equilibrium is that of the adult Drosophila intestine. In this organ, division is coupled to death because Rhomboid, a protease that cleaves mitogenic EGFs for secretion, is induced in cells undergoing apoptotic elimination [8] . In Drosophila, as in mammals, intestinal stem cells give rise to adenomas following loss of adenomatous polyposis coli (APC) [9] . Examining Drosophila APC -/tumorigenesis, we find that pre-tumor cells destabilize cell equilibrium by uncoupling rhomboid from apoptosis, which creates feed-forward amplification of EGF signaling for tumor establishment. Prior to tumor formation, APC -/cells induce rhomboid in surrounding cells via activation of the stress signal JNK. During subsequent growth, APC -/tumors induce rhomboid within the tumor itself via loss of E-cadherin and consequent activity of p120-catenin. Chronic induction of rhomboid in both tumor and surrounding cells leads to constitutive activation of EGFR and is essential for tumors to progress. Thus, incipient tumors combine non-autonomous and autonomous strategies to deregulate rhomboid and destabilize cell equilibrium. Since Rhomboid, EGFR, and E-cadherin are associated with colorectal cancer in humans [10] [11] [12] [13] [14] [15] [16] [17] , our findings may shed light on how human colorectal tumors progress.
Results and Discussion
To investigate how tumors subvert cell equilibrium in the Drosophila intestine (midgut), we generated intestinal stem cells that were null for APC ( Figures 1A, S2A) and allowed them to initiate tumorigenesis. Low-frequency, hs-flp-mediated MARCM recombination [18] was used to produce a sparse distribution of stem cells that were (1) marked by heritable expression of GFP and (2) either control genotype or else homozygous for null alleles of Drosophila APC1 and APC2 (APC -/-) [19, 20] ( Figure   S2A ).
As described previously [21] [22] [23] [24] [25] , APC -/stem cells frequently gave rise to multilayered adenomas over a period of 2-3 weeks (Figure S1B-E). At 2 days after induction, all APC -/clones were single-layered ( Figure S1E ). By 5 days after induction, 6.8 1.9% of APC -/clones were multilayered. By 21 days after induction, 36.2 1.7% of APC -/clones were multilayered. In addition, APC -/clones grew larger than control clones. Whereas most 21-day control clones contained fewer than 50 cells, many 21day APC -/clones contained 100-500 cells ( Figure 1G ). These large, multilayered clones formed prominent masses that protruded into the midgut lumen ( Figure S1D ), a phenotype reminiscent of APC-inactivated colonic adenomas in humans [26] .
As human APC cancers progress, they often lose expression of the tumor suppressor E-cadherin [27, 28] . We therefore examined whether APC -/tumors in the Drosophila midgut exhibit loss of E-cad (also known as shotgun). In control tissue, E-cad::mTomato [29] localized prominently to lateral cell membranes, as expected ( Figure 1B) [8] . In APC -/clones that were single-layered, E-cad::mTomato also localized to lateral membranes, consistent with prior work [22] ( Figure 1C ). In APC -/clones that were multilayered, however, E-cad::mTomato localized to membranes inconsistently and, in supra-basal layers, was often absent ( Figures 1B, 1C) . These observations suggest that Drosophila APC -/tumors, like their human counterparts, downregulate E-cad as they become more advanced.
Since human E-cad is an epithelial tumor suppressor, we wondered whether forced expression of E-cad would suppress tumor formation. To test this possibility, we generated APC -/stem cells that additionally overexpressed E-cad and assessed their tumorgenicity ( Figures 1D, S3A ). APC -/-, E-cad stem cells gave rise to clones that were markedly smaller than those generated by APC -/stem cells ( Figures 1F, 1G ).
Furthermore, APC -/-, E-cad clones generally maintained normal tissue structure.
Whereas many APC -/clones became multilayered after 21 days, the vast majority of APC -/-, E-cad clones remained single-layered ( Figure 1H ). Thus, analogous to human epithelia, E-cad acts as a tumor suppressor in the Drosophila midgut.
We sought to determine how E-cad suppresses midgut tumorigenesis. A prevailing model is that loss of E-cad promotes tumor progression by weakening cellcell adhesion to enable tumor cell invasion. To test whether tumor suppression by E-cad involves adhesion, we forced APC -/stem cells to overexpress E-cad dCR4h , an allele that lacks extracellular adhesion motifs ( Figure 1E ) [30] . Despite being adhesionincompetent, E-cad dCR4h was equally as effective as wild-type E-cad at preventing APC -/clone overgrowth and multilayering ( Figures 1G, 1H) . These results show that tumor suppression by Drosophila E-cad does not require cadherin-mediated extracellular adhesion.
We considered an alternate model in which E-cad suppresses tumorigenesis by binding p120-catenin (p120) [31] . During steady-state turnover, E-cad inhibits the transcriptional activity of p120 [8] (Figure S1A ), likely by sequestering it at the cortex of mature enterocytes. This interaction prevents p120 from inducing rhomboid, an intracellular protease whose expression enables secretion of EGFs and consequent divisions of stem cells [8] .
To test the role of the E-cad-p120 interaction in tumor suppression, we forced APC -/stem cells to express E-cad ΔJM , an allele with a juxtamembrane deletion that abrogates binding of p120 but not -catenin or β-catenin (also known as Armadillo) [32] .
Unlike E-cad and Ecad dCR4h , E-cad ΔJM failed to suppress tumorigenesis. APC -/-, E-cad ΔJM clones grew to sizes comparable to APC -/clones, and a similar proportion became multilayered ( Figures 1G, 1H ). These findings imply that binding of E-cad to p120 is crucial for tumor suppression.
Another E-cadherin-associated transcription factor, β-catenin, is known to contribute to APC-driven tumorigenesis in both Drosophila midgut and mammalian intestine [21, 22, 33, 34] However, β-catenin indiscriminately associates with E-cad alleles that are tumor-suppressive (E-cad and Ecad dCR4h ) and with alleles that are tumor non-suppressive (E-cad ΔJM ) ( Figure 1E ). Thus, the capacity for each E-cad to rescue tumor growth cannot be attributed to differences in β-catenin sequestration.
If the E-cad-p120 interaction suppresses tumorigenesis by sequestering p120, then loss of p120 should also suppress tumorigenesis. To test this prediction, we depleted p120 from APC -/stem cells using RNAi. Double APC -/-, p120RNAi clones accumulated significantly fewer cells and exhibited less multilayering compared to APC -/clones ( Figures 1G, 1H ). These findings, combined with the loss of tumor suppression by E-cad ΔJM , imply that downregulation of E-cad promotes tumorigenesis by deregulating p120.
We had previously identified that p120 activates transcription of rhomboid in apoptotic enterocytes during steady-state turnover [8] . Since p120 is necessary for APC -/tumor development, we wondered whether rhomboid is also necessary. First, we examined expression of a rhomboid-lacZ reporter (Figure 2A ). Flp/FRT recombination was used to generate unlabeled, APC -/stem cells in a background of GFP-labeled cells ( Figure S2B ) [24] ; both APC -/and background cells possessed the rhomboid-lacZ transgene.
We observed widespread expression of rhomboid in midguts containing APC -/tumors. After 21 days of clone development, rhomboid was expressed by 15.3 12.4% of cells in APC -/clones but only 1.7 3.4% of cells in control clones (Figures 2A-C ).
Furthermore, in midguts that contained APC -/clones, rhomboid was expressed by 20.0 12.7% of non-clone background cells, whereas in midguts that contained control clones, rhomboid was expressed by only 2.1 1. Our prior work showed that during normal turnover, rhomboid is suppressed in healthy enterocytes and induced in apoptotic enterocytes ( Figure S1A ) [8] . This regulatory mechanism gives rise to tissue-level cell equilibrium by spatiotemporally coupling the release of EGFs that are essential for stem cell division to the loss of terminally differentiated cells that need replacement. Since cell equilibrium must be disrupted for tumors to form, we wondered whether regulated expression of rhomboid was also disrupted.
Examining midguts with APC -/clones, we observed that the vast majority of rhomboid-expressing cells were non-apoptotic. In APC -/clones, 92.7  3.7% of rhomboid-expressing cells lacked caspase activation ( Figure 2D ). In the tissue surrounding APC -/clones, 89.0  2.9% of rhomboid-expressing background cells lacked caspase activation ( Figure 3B ). These findings imply that tumor-associated hyperinduction of rhomboid, unlike steady-state induction of rhomboid, does not require apoptosis.
Since Rhomboid enables EGF secretion, hyper-induction of rhomboid should lead to hyperactivation of EGFR. To test this prediction, we performed immunostaining for the activated, di-phosphorylated form of the EGFR effector Erk (dpErk) [4, 8, 22, 35] .
We found that 30.7  17.0% of cells in APC -/clones exhibited dpErk, compared to just Does hyper-induction of rhomboid drive APC -/tumorigenesis? We first examined whether developing tumors require tumor-autonomous rhomboid production. MARCM was used to generate GFP-labeled, APC -/stem cells that were additionally depleted of rhomboid ( Figure S3A ). These APC -/-, rhomboid-knockdown stem cells formed clones that were smaller than those formed by APC -/stem cells ( Figures 2G, 2H ). Moreover, the vast majority of APC -/-, rhomboid-knockdown clones did not become multilayered ( Figure 2I ). Consistent with these phenotypes, depletion of egfr from APC -/stem cells also prevented clone growth and multilayering ( Figures 2G, 2H , 2I), similar to prior reports [4, 22, 35] . Thus, hyper-induction of rhomboid within nascent APC -/tumors is required for tumor growth and progression, likely via hyperactivation of EGFR.
We next assessed whether tumor development requires non-autonomous production of rhomboid in background cells. To manipulate gene expression specifically in background cells and not in APC -/tumor cells, RU486-inducible RNAi knockdown in background cells was combined with Flp/FRT recombination to generate APC -/stem cells that were unresponsive to RU486 (Figures 3C, S2C, S3B) [24] . Additional inclusion of a recombination-sensitive RFP transgene enabled background cells and APC -/cells to be distinguished as RFP-labeled and unlabeled, respectively.
Using this system, we found that depletion of rhomboid in background cells caused a marked reduction in both the sizes of APC -/clones and the frequency of These findings provide insight into how cell equilibrium becomes destabilized for tumor formation. The requirement for egfr in tumor cells and not background cells implies that tumor growth is driven by tumor-autonomous hyperactivation of EGFR. By contrast, the dual requirement for rhomboid in tumor cells and in background cells suggests that non-apoptotic cells in both populations must chronically produce EGFs to overcome robust mechanisms of cell equilibrium.
How do incipient tumors incite non-apoptotic background cells to express
rhomboid? An appealing possibility involves stress signaling via the Jun N-terminal kinase (JNK; also basket or bsk in Drosophila). Prior work has shown that growth of APC -/tumors requires JNK in both tumor cells and background cells [24] . Furthermore, regeneration of damaged midguts is accompanied by widespread induction of rhomboid [36, 37] . These precedents raise the possibility that APC -/cells influence background cells to express rhomboid via JNK.
To investigate this possibility, we compared the kinetics of JNK and rhomboid in background cells as tumors developed over time. Unmarked APC -/stem cells were generated in a background of GFP-labeled cells using Flp/FRT recombination ( Figure   S2B ). Midguts were harvested at 2, 5, 10, or 21 days after clone induction ( Figure 4A Interestingly, both JNK activation and rhomboid hyper-induction occurred in background cells before occurring in APC -/cells ( Figure 4B ). Furthermore, at 5 days after clone induction, when activated JNK was first detected in background cells ( Figures 4B, 4C ), the morphology of APC -/clones still resembled control clones. This timing suggests that nascent APC -/clones elicit non-autonomous JNK activation in their neighbors even before the clones form multilayered tumors.
We noticed that, 5-21 days after clone induction, pJNK was exhibited by ~80% of rhomboid-expressing background cells ( Figure 4E ). This high coincidence raised the possibility that JNK acts directly in background cells to induce rhomboid. To test this notion, the genetic system in Figures S2C and S3B was used to generate APC -/stem cell clones and, concomitantly, inhibit JNK in background cells via expression of dominant negative bsk (bsk DN ) [38, 39] . Expression of bsk DN specifically in background cells was sufficient to decrease levels of rhomboid mRNA by ~40% ( Figure 4F ). Since rhomboid is essential for tumorigenesis, we conclude that incipient tumors enable their own growth by JNK-mediated induction of rhomboid in surrounding cells.
Perspective
In summary, we have shown that APC -/cells require both autonomous and nonautonomous deregulation of the EGF protease rhomboid to disrupt cell equilibrium and generate tumors. Before APC -/cells develop into tumors, they induce rhomboid in nonapoptotic background cells by activating JNK. Once tumors are established, they autonomously activate rhomboid via loss of E-cadherin and release of p120-catenin.
Deregulation of rhomboid in both tumor cells and background cells is required for multilayered adenomas to form. This dual requirement implies that high levels of EGFs are necessary to subvert robust mechanisms of cell equilibrium.
During steady-state turnover, precisely regulated induction of rhomboid controls cell equilibrium by coupling division to death: Because rhomboid is normally induced in cells undergoing apoptotic elimination, mitogenic EGFs are produced at the specific time and place that replacement cells are needed. For APC -/cells to disrupt cell equilibrium, they must instigate widespread induction of rhomboid in cells that are nonapoptotic ( Figure 4G ). Non-apoptotic induction of rhomboid effectively decouples cell division from cell death by enabling EGFs to be produced chronically. Constitutive production of EGFs drives continual production of new cells irrespective of tissue need.
This mechanism of APC -/tumor establishment in Drosophila may shed light on initiation of human colorectal cancers, which are tightly associated with inactivating mutations in APC. Intriguingly, Rhomboids, E-cadherin, and EGFR have all been implicated in progression of the human disease [13, 17, [40] [41] [42] , suggesting that this tumorigenic signaling axis may be conserved. In this regard, two of our findings carry particular interest: First, while loss of E-cad is canonically thought to promote metastasis via loss of cell-cell adhesion, our findings reveal a new role during earlytumor development: deregulation of p120-catenin to drive EGF signaling. To our knowledge, the role of p120-catenin in colorectal cancer has not been investigated.
Second, we find that induction of rhomboid is a tumor-initiating event, whereas studies (E) Domain structure of wild-type (wt) E-cad and mutant E-cad alleles that lack either the extracellular adhesion domain (E-cad dCR4h ) [30] or the intracellular binding domain for p120-catenin (E-cad ΔJM ) [32] . In all three systems, all midgut cells are initially unlabeled and heterozygous for null alleles of APC1 (APC1 Q8 ) and APC2 (APC2 G10 ). Heat shock induces expression of flp recombinase, which catalyzes recombination in mitotic stem cells to generate a daughter cell that is homozygous for both APC1 Q8 and APC2 G10 (APC -/-). Fig. 1F-H hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82 hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-E-cad; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-E-cad dCR4h ; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-E-cad ΔJM ; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-p120 RNAi; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Figure 2 Fig. 2B-C hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82 Fig. 2B-D hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82, APC2 G10 , APC1 Q8 Fig. 2E-F hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82 hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Fig. 2G-I hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82 hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-egfr RNAi; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 hsflp, UAS-GFP; tubGAL4 / UAS-rho RNAi; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Figure 3 Fig. 3A hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82 Fig. 3A-B hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82, APC2 G10 , APC1 Q8 Fig. 3D-F hsflp; FRT82, GS2326, ubi-RFP / FRT82 hsflp; FRT82, GS2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 hsflp; UAS-egfr RNAi; FRT82, GS2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 hsflp; UAS-E-cad; FRT82, GS2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 hsflp; UAS-p120 RNAi; FRT82, GS2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 hsflp; UAS-rho RNAi; FRT82, GS2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 Figure 4 Fig. 4B-E hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82, APC2 G10 , APC1 Q8 Fig. 4F hsflp; FRT82, GS2326, ubi-RFP / FRT82 (reference cDNA) hsflp; FRT82, GSG2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 hsflp / UAS-bsk DN ; FRT82, GSG2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 Figure S1 Fig. S1B hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Fig. S1D hsflp, UAS-GFP; tubGAL4 / E-cad mTomato ; FRT82 tubGAL80 / TM6B hsflp, UAS-GFP; tubGAL4 / E-cad mTomato ; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Fig. S1E hsflp; rho-lacZ (rho X81 ), FRT82, ubi-GFP / FRT82, APC2 G10 , APC1 Q8 Figure S2 Fig. S2A hsflp, UAS-GFP; tubGAL4; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Fig. S2B hsflp; FRT82, ubi-GFP / FRT82, APC2 G10 , APC1 Q8 Fig. S2C hsflp; FRT82, GSG2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 Figure S3 Fig. S3A hsflp, UAS-GFP; tubGAL4 / UAS-X; FRT82 tubGAL80 / FRT82, APC2 G10 , APC1 Q8 Fig. S3B hsflp; UAS-X; FRT82, GSG2326, ubi-RFP / FRT82, APC2 G10 , APC1 Q8 'GS2326' denotes the GeneSwitch driver, P[Switch]GSG2326 [24] .
'UAS-X' generically denotes a UAS-driven transgene of interest (ex: UAS-E-cad) One of three repetitions is shown for each experiment; numbers of clones per experiment vary between repetitions. Figure 1C , both early-and late-stage tumors were quantified from the same midguts (n = 4).
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Materials and Methods
Drosophila husbandry
Adult female flies were used in all experiments. Crosses and adult flies were raised at 25°C. Unless specified otherwise, flies were heat-shocked 1 day after eclosion to induce clones and collected 21 days after induction for dissection/ immunostaining. See
Supplementary Table 1 for full list of experimental genotypes.
Fly stocks
The following stocks were obtained from the Bloomington Stock Center: y w shg mTomato , 
Immunohistochemistry and microscopy
Samples were fixed, immunostained and mounted as previously described [8, 45] . Anti-GFP and anti-RFP antibodies were used to improve detection of ubi-GFP and ubi-RFP expression in tumor labeling systems ( Figure S2 ). Anti-RFP was used to detect anti-rabbit, anti-mouse, or anti-chicken IgGs (1:800, LifeTechnologies A31570, A11001, A11039, A32728, A32732, and A21244). Nuclei were stained with DAPI (LifeTechnologies, 1:1,000). Samples were mounted in ProLong (LifeTechnologies).
Imaging of samples was performed on a Leica SP8 confocal microscope, with serial optical sections taken at 3.5-μm intervals through the entirety of whole-mounted, immunostained midguts.
Induction of stem cell clones
Tumor clones were generated using three separate labeling systems ( Figure S2 ). For all three labeling systems, tumor clones were generated by collecting adult flies one day post-eclosion and performing two 30-min, 38.5°C heat shocks separated by a 8-min chill on ice. Flies were returned to 25°C until time of dissection. For experiments which manipulated gene expression in adjacent tissue after tumor induction ( Figure S2C ; also known as the "pLoser" system [24] ), flies were fed RU486 upon returning to 25°C postheat shock until time of dissection (see "GeneSwitch induction" below).
Clone visualization and cell counts
Tumors were visualized (1) as z-stacks using Fiji [46] and (2) in 3D using the Bitplane Imaris software. For each midgut, all clones within the R4 and R5 regions [43] were analyzed (see Figure S1B ). Cells per tumor were measured as the number of DAPI + nuclei within the labeled clone boundary (as determined by the presence or absence of respective labeling proteins). All clone counts were performed manually. To categorize tumors as single-layered or multilayered, each tumor was viewed from the sagittal plane in Bitplane Imaris.
GeneSwitch induction
To induce expression of the GeneSwitch driver, GS2326, adult flies were fed RU486.
RU486 (Sigma-Aldrich) was dissolved in dH2O to reach a working concentration of 25 µg/mL. This solution was used to prepare yeast paste, which was fed to flies as a supplement to their standard cornmeal-molasses diet for the duration of induced gene expression. Drug-containing yeast paste was replenished every three days.
qRT-PCR
mRNA was extracted from whole midguts (four midguts per biological replicate) followed by cDNA synthesis with Invitrogen SuperStrand III First Script Super Mix (Invitrogen).
Real-time PCR was performed using the relative standard curve method with SYBR GreenER Supermix (Invitrogen) on a StepOnePlus ABI machine. Each biological replicate was assessed in three technical replicate experiments. Expression levels were normalized to non-tumorous midguts expressing control clones; rp49 transcripts were used as a reference. Primers were from [8, 47] . Primer sequences from 5' to 3' -rp49
Fwd: CGGATCGATATGCTAAGCTGT, rp49 Rev: CGACGCACTCTGTTGTCG, rhomboid Fwd: GAGCACATCTACATGCAACGC, and rhomboid Rev:
GGAGATCACTAGGATGAACCAGG.
Statistical analysis
All statistical analyses were performed using Graphpad Prism 7. For comparisons of clone size distributions, unpaired two-tailed Mann-Whitney U-tests were used to assess statistical significance. To compare the frequencies of mutilayered clones, cell numbers or percentages, and mRNA levels, unpaired two-tailed t-tests were used to assess statistical significance.
Study design
Sample sizes were chosen based on our previous studies [8, 45] , which also characterized changes in clone sizes and midgut cell numbers; see also Supplementary   Table 2 . No exclusion criteria were applied. No sample randomization or blinding was performed.
